about
Imatinib mesylate in chordomaSteroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma.Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient.Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution.Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution.Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1.Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution.Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma.Expression of ligand-activated KIT and platelet-derived growth factor receptor beta tyrosine kinase receptors in synovial sarcoma.Complete response after rechallenge with trabectedin in a patient with previously responding high-grade undifferentiated sarcoma.Unusual sites of Ewing sarcoma (ES): a retrospective multicenter 30-year experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP) and Italian Sarcoma Group (ISG).Epithelioid sarcoma: prognostic factors and survival in a series of patients treated at a single institution.Retroperitoneal soft tissue sarcomas: patterns of recurrence in 167 patients treated at a single institution.Oncogenic and ligand-dependent activation of KIT/PDGFRA in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs).Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal TrialRapid-onset opioids for the treatment of breakthrough cancer pain: two cases of drug abuse.High-grade soft-tissue sarcomas: tumor response assessment--pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria.Primary Ewing's sarcoma of the sinonasal tract in adults: A challenging disease.At the crossroads of molecular biology, pathology and the clinic.c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors.Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion.Cytokeratin Immunoreactivity in 41 Cases of ES/PNET Confirmed by Molecular Diagnostic StudiesPrognostic Effect of Re-Excision in Adult Soft Tissue Sarcoma of the ExtremityStatus of Surgical Margins and Prognosis in Adult Soft Tissue Sarcomas of the Extremities: A Series of Patients Treated at a Single Institution
P50
Q28282621-11DE5A66-802E-424A-81F7-E6C1CA672E29Q33371397-229314BC-79E3-455E-9BD7-A177E8E690FEQ33419286-9DF94A5A-8E68-422A-B2F5-E95F27BB39EEQ33817421-76B072BA-6F17-47DB-AD3B-2F95AF3A35CBQ34331384-7882A839-A1C1-47A0-95F9-10D3AD537E1AQ34532365-C7625837-6214-4461-84A6-BB19864603B2Q34549587-9FAAF50D-5A67-4600-A5C0-320FA3C9D550Q34551403-72A4CD7A-7423-4C4E-BE29-E2AC622610F5Q34638074-4F31B034-D8B4-4FCB-A8D3-4F12EF7E565BQ35184350-E36D0BDD-B08C-4E65-A7BF-5FDCDE798F0CQ39669916-FE50668A-7CE2-4095-9414-D33962990D7CQ40590667-1FDF60D8-38F2-48E2-8058-5DB099C5AE91Q41008543-111901E9-FCBF-4656-8675-1EF51B114201Q44778671-E8D11082-03C6-4FD4-BB11-72DC82FB2256Q44830728-4578A0F5-1F06-46F4-BA55-4BBA9D2F333CQ45257998-F9829624-A384-4C47-BFD3-AAB759517053Q46273752-355881EB-7C20-452E-92EF-8849A6854844Q46658501-00D68727-3D97-4972-8D36-C2D173538666Q47851937-59EBEDDC-C8E5-4BDD-896A-18272A073B91Q51849514-1174D6A0-21DE-4536-A858-231EA46E026DQ52952634-DE863536-56A1-4918-BC3A-46F421F43A41Q53128219-39BD13B0-3998-4B9F-ADC1-64CDC6157975Q53559201-D1386E2A-919F-4F3E-8C7F-9B4C5E004C87Q54084719-6EFD251C-27CA-47B8-B5EE-4FBD703EA2D3Q59287294-2DA3C00F-AA54-4882-98EB-A7B251798753Q61623001-89131B92-FF40-4545-BFA5-0DAB85C5D5DAQ61623008-096DDF34-71F4-4617-999B-A9C07B913752
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Rossella Bertulli
@ast
Rossella Bertulli
@en
Rossella Bertulli
@es
Rossella Bertulli
@nl
Rossella Bertulli
@sl
type
label
Rossella Bertulli
@ast
Rossella Bertulli
@en
Rossella Bertulli
@es
Rossella Bertulli
@nl
Rossella Bertulli
@sl
prefLabel
Rossella Bertulli
@ast
Rossella Bertulli
@en
Rossella Bertulli
@es
Rossella Bertulli
@nl
Rossella Bertulli
@sl
P106
P31
P496
0000-0002-7237-7515